Spots Global Cancer Trial Database for A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Official Title: An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors
Study ID: NCT06244771
Interventions
Study Description
Brief Summary: The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
START Mountain Region, West Valley City, Utah, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
Contact Details
Name: Andrew Krivoshik, MD, PhD
Affiliation: Frontier Medicines Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
